Lataa...
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
BACKGROUND: A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma has been identified as a predictor of superior long-term outcome in some, but not all studies. METHODS: To determine if the parameter of M protein reduction was of value in the rela...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4149315/ https://ncbi.nlm.nih.gov/pubmed/21328327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25937 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|